"MEET-THE-EXPERT" SUNRISE SESSIONS

Drug Resistance (Susan P. C. Cole)
Cancer Screening (Barnett S. Kramer)
Molecular Signaling of CML (Jean Y. J. Wang)
Apoptosis and Chemotherapy (John A. Hickman)
Caspases (Nancy A. Thornberry)
Molecular Cytogenetics (Joe W. Gray)
p53 Gene Therapy-mediated Radio/Chemosensitization (Esther H. Chang)
The Genetics of Multiple Endocrine Neoplasia Type 2 (MEN 2) (Bruce A. J. Ponder)

Differentiation Therapy (Samuel Waxman)
AIDS-related Malignancies (Ellen G. Feigal)
Tumor Vaccine Therapy (Michael T. Lotze)
Integration of Biological Agents into Radiotherapy (William H. McBride)
Molecular Detection of Minimal Residual Disease (Theodore F. Zipf)
Microsatellite Instability (David Sidransky)
Chemoprevention Trials: Science vs. Art vs. Fantasy (David S. Alberts)
Genetic Imprinting (Andrew P. Feinberg)
Cancer Metastasis: Cellular and Clinical Studies (David Tarin)
Embryonal Stem-cell-based Technology (Randall Johnson)
Replicative Senescence (Judith Campisi)
Drug Design and Development (Randall K. Johnson)
In Vivo Imaging of Gene Expression in Solid Tumors (Ralph Weissleder)
The RB Family and CDKs in the Cell Cycle in Cancer (Antonio Giordano)
Prospects for Biological Agents (Peter J. Houghton)
Disorders in Cell Circuity in Cancer (I. Bernard Weinstein)
bc2: Its Family and Modification (Timothy J. McDonnell)
Topic to be Announced (Franklyn Prendergast)
Chemoprevention in Respiratory Cancer (Lee W. Wattenberg)
TGF-β and Colon Cancer (Sanford Markowitz)
Inherited Susceptibility to Breast and Ovarian Cancers (Funmi I. Olopade)
VEGF (Harold F. Dvorak)
Origins of Melanoma (Margaret A. Tucker)
Biography of Premalignant Lesions (Walter N. Hittelman)
Genetic Determinants of Prostate Cancer (William B. Isaacs)
DNA Repair: Breaking Cycle-specific Constraints in Combination Therapy (William K. Plunkett)
Antisense Therapies (Stanley T. Crooke)
Topic to be Announced (Nagahiro Saito)
Small Molecule Inhibitors of Protein Kinases That Block Tumor Angiogenesis for the Treatment of Cancer and Metastasis (Jerri McMahon)
Integration of Biological Agents into Chemotherapy (Herbert M. Pinedo)
New Therapeutic Agents (Michael C. Christian)
Function and Target Genes of myc in Neoplasia and Apoptosis (Chi Van Dang)
Isolation of Genes Regulated by p53 or β-catenin and Their Roles in Human Carcinogenesis (Yusuke Nakamura)
Behavioral Oncology (Barbara K. Rimer)
Mdm2 (Guillemína Lozano)
Molecular Processes in DNA Repair After Irradiation (Gloria C. Li)
Natural Agents and Chemoprevention (Hirotu Fujiki)
The Genetics of Wilms Tumor (Michael R. DeBaun)
Prevention and Treatment of Breast Cancer (Martin D. Abeloff)

Further Information: AACR Office • Public Ledger Building, Suite 826
150 S. Independence Mall West • Philadelphia, PA 19106-3483
Telephone: 215-440-9300 • FAX: 215-440-9313
E-mail: meetings@aacr.org • Website: http://www.aacr.org
At Amgen, you’ll discover a research environment that emphasizes collaboration, intellectual honesty, scientific integrity, and a supportive culture. This unique approach has helped us grow into a global biotechnology leader in just 18 years. We are seeking research associates with a background in cancer-related research to work in our Cancer Biology program at Amgen.

Research Scientist
(Job Code: 000000137)
You will work in an exciting, fast-paced, state-of-the-art environment to discover novel genes and pathways that regulate specific aspects of tumor genesis. Positions are available for scientists with research experience in areas related to apoptosis, angiogenesis, cell adhesion, tumor biology and development of in vitro and in vivo assays for high-throughput screens. The cancer biology group collaborates with multiple groups within Amgen, including: protein chemistry, small molecule chemistry, high-throughput screening, microarray and microprocessing, functional genomics and proteomics. The wide range of resources available at Amgen enables scientists to rapidly discover, characterize and validate potential therapeutic targets. You must possess a Ph.D. in a molecular, biochemistry or cell biology program, with a minimum 3 years of postdoctoral experience in cancer-related research. A strong background in cancer research, a proven publication track record, a drive to succeed and an ability to work in a team-oriented environment are key to your success.

Research Associate
(Job Code: 000000138)
You will work with a select group of scientists who are discovering novel genes and examining signal transduction pathways that are altered during tumor genesis. We are seeking highly motivated individuals who are not only able to work efficiently in a team-oriented environment, but also capable of designing experiments and thinking independently. You must possess technical experience in one or more of the following areas: molecular biology, protein biochemistry, genomics, mammalian cell culture and protein purification. A research background in apoptosis, angiogenesis, cell cycle, in vivo tumor models and tumor biology is preferred. A minimum of a Bachelor’s degree in Science is required, a Master’s degree or research experience in an academic or industrial setting is highly desirable.

At Amgen, your accomplishments are rewarded. We offer a highly competitive compensation and benefits package that includes a retirement and savings plan, an on-site fitness center and three weeks' vacation. For immediate consideration, please mail your resume on plain white paper (indicating appropriate job code, using standard type and fonts, no bullets, italics, underlining or bolding), to: Amgen, Staffing, P.O. Box 2569, Thousand Oaks, CA 91359-2569, or email your ASCII text resume to: jobs@amgen.com. Please consult our Web Site at www.amgen.com for information on other career opportunities available at Amgen. Principals only, please. We recognize that diverse perspectives are a key in the process of discovery.

EOE/AA Employer M/F/D/V.

Director of Research
Arkansas Cancer Research Center
University of Arkansas for Medical Sciences

The Arkansas Cancer Research Center (ACRC) at the University of Arkansas for Medical Sciences (UAMS) seeks nominations and applications for a Director of Research. Applicants must have an MD, PhD, or equivalent degree, and major administrative experience. He/she should have an active, funded program in basic and/or clinical cancer research. The candidate’s scope, knowledge, and interest in cancer research should be sufficiently broad so that he/she can effectively interact with and facilitate the integration of the various research programs at the center.

The Director of Research will oversee the overall development, coordination, and implementation of basic and clinical research at the ACRC. Specifically, the Director of Research will: (i) play a major role in the integration and expansion of existing research programs, (ii) monitor the progress of ongoing basic and clinical research in order to enhance and facilitate research productivity and inter-programmatic collaborations, (iii) facilitate initiation and conduct of collaborative studies with clinical and basic science departments at UAMS and other nearby institutions, (iv) identify specific areas of research to be developed and participate actively in recruiting new investigators, (v) be responsible for the allocation of research space, procurement and allocation of research equipment, education of medical students, graduate students, and fellows, and (vii) advise the ACRC Director in budgetary and general organizational issues. The Director of Research will have an appointment in an academic department at UAMS and report directly to the ACRC Director. Send applications and curriculum vitae to:

Bart Barlogie, MD, PhD, Director
Arkansas Cancer Research Center
4301 West Markham, Slot 623
Little Rock, AR 72205

University of Arkansas for Medical Sciences is an Affirmative Action/Equal Opportunity Employer.
ASSISTANT/ASSOCIATE/PROFESSOR HEMATOLOGY/ONCOLOGY

The Section of Hematology/Oncology and the Department of Medicine, University of Arizona College of Medicine, is seeking faculty members for its expanding programs in benign and malignant hematologic diseases, blood disorders, and lung cancer. The Hematology and Oncology Section is a multi-disciplinary group within the Arizona Cancer Center which is committed to Clinical and Translational Research in all aspects of cancer, cancer patient care, and teaching, as well as being an active member of the Southwest Oncology Group. Medical or Osteopathic degree, BE/BC in Internal Medicine and/or Medical Oncology and teaching experience are required. Position includes postgraduate training and medical student instruction. Send CV and a list of at least three references to David S. Alberts, M.D., Arizona Cancer Center, 1515 N. Campbell Ave., Tucson, AZ 85724. Academic rank, tenure status and salary will be commensurate with qualifications and experience. See http://w3.arizona.edu/~ahschr/jobs.htm; reference Job #996275. Application review begins 1/4/99 and will continue until position is filled. The University of Arizona is an EEO/AA/employer-M/W/D/V.

UNIVERSITY OF TORONTO
Department of Nutritional Sciences,
Faculty of Medicine

Applications are invited for a Contractually Limited Term Appointment at the Assistant Professor level in the Department of Nutritional Sciences, Faculty of Medicine, University of Toronto. This appointment will be effective July 1, 1999, initially for 3 years.

Applicants should hold a Ph.D. with a strong record of research on the mechanism of dietary effects on cancer development.

Applicants will be expected to mount an independent research program and to teach at the undergraduate and/or graduate levels.

Salary will be commensurate with qualifications and experience.

Applicants should send their curriculum vitae, with the names of three referees to: Dr. Michael C. Archer, Chair, Department of Nutritional Sciences, Faculty of Medicine, University of Toronto, FitzGerald Building, 150 College Street, Toronto, Ontario, Canada MSS 3E2.

Application deadline is February 15, 1999.

In accordance with its Employment Equity Policy, the University of Toronto encourages applications from qualified women and men, members of visible minorities, aboriginal peoples and persons with disabilities. In accordance with Canadian Immigration requirements, this advertisement is directed to Canadian citizens and permanent residents.

ANTI-CANCER Compounds

PACLITAXEL
Extracted from bark of Taxus Yunnanensis
GMP standard, minimum 99.0%

Other Taxane Compounds also available
Cephalomannine, 10-DAB, Baccatin III
7-Epi-10-Deacetyl Paclitaxel, etc

Other compounds
Bleomycin Sulfate Carboplatin
Camptothecin Cisplatin
Daunorubicin Doxorubicin
Etoposide Mitomycin
Tamoxifen Citrate Many others
(For research purposes only)

(Hande Tech USA, Inc.
7322 Southwest Freeway, Suite 1888
Houston, TX 77074, USA
Tel: (713) 777-7088 Fax: (713) 777-7091
Email: market@handetech.com
http://www.hande.com)
Purdue University
Walther Professor of Nutrition and Cancer

The Department of Foods and Nutrition at Purdue University, in collaboration with the Purdue Cancer Center, and with the support of the Walther Cancer Institute, is seeking a nationally recognized scientist to fill a new position in the area of nutrition and cancer. The position offers an opportunity to expand a strong research program through collaborations with more than 100 campus scientists currently engaged in basic cancer research who possess expertise in biological, biochemical and chemical sciences, engineering, pharmacology, veterinary medicine and nutrition. The successful candidate will have an appointment in the Departments of Foods and Nutrition, but will be closely affiliated with the Purdue Cancer Center (a National Cancer Institute designated basic laboratory research center since 1978 housing programs in experimental therapeutics and diagnostics, structural biology, cell growth and differentiation and carcinogenesis). The position is available immediately.

The successful candidate is expected to qualify for the rank of FULL PROFESSOR. He/she will have a PhD, DVM or MD degree with a distinguished track record in research as measured by extramural research funding and peer-reviewed publications and evidence of productive collaborative research activities. Teaching experience is also desirable. There are no clinical practice responsibilities. A highly competitive salary and benefits package is available.

An application should include a description of interest outlining current and planned research and scholarly activities, three representative reprints, curriculum vitae and names, addresses and phone numbers of three references. The review of applications is ongoing and will continue until the position is filled. Send materials to: Richard Mattes, PhD, Purdue University, Dept of Foods and Nutrition, 1264 Stone Hall, West Lafayette, IN 47907-1264, 765-494-0662/FAx 765-494-0674

Purdue University provides the resources and amenities of a big ten university in a setting that offers a high quality of life. Purdue is an Equal Opportunity, Affirmative Action Employer.
CALL FOR APPLICATIONS IN CLINICAL CANCER RESEARCH

The Cancer Treatment Research Foundation, a non-profit, 501(c)(3) organization, is accepting applications for new and pilot/feasibility clinical projects in cancer therapy. These areas include new, innovative anticancer therapies, biological response modifiers, immunotherapy, gene therapy, quality of life, and nutritional oncology. All interested applicants should send a letter of intent to:

Joni L. Shulman
Grants Administrator
Cancer Treatment Research Foundation
3455 Salt Creek Lane, Suite 200
Arlington Heights, Illinois 60005

Alternately, you may call Joni Shulman at the number below to confirm an intent to submit an application. The initial, first phase application will be in the form of a two or three page concept proposal including background, rationale, study design, budget, and significance of the project in relation to the overall mission of CTRF. The concept proposal will be reviewed by selected members of the Board of Scientific Counselors of CTRF. Investigators whose preliminary proposals are approved by the Board will be invited to submit a formal application. Preliminary applications may be submitted at any time.

Should you have questions, please call Joni Shulman at (847) 342-6484.

Postdoctoral Research Fellowship in Molecular Oncology

The Center for Molecular Medicine at the University of Connecticut School of Medicine invites applications for a postdoctoral fellowship to (a) pursue novel approaches toward understanding the role of the cyclin D1 oncogene in human neoplasia and in relevant animal models, and (b) exploit this understanding for therapeutic purposes.

A strong background in molecular biology is required, and experience in molecular oncology is highly desirable.

Review of applications will begin on January 1, 1999, and will continue until the position is filled. Send curriculum vitae, statement of research experience and interests, and names of three references to:

Dr. Andrew Arnold
Director, Center for Molecular Medicine
University of Connecticut School of Medicine
263 Farmington Avenue
Farmington, CT 06030-1316

CANCER BIOLOGISTS

The Department of Medicine and the Duke Comprehensive Cancer Center are soliciting applications for research faculty with expertise within the broad area of cancer biology. Individuals with a PhD or MD/PhD are being recruited at the Assistant or Associate Professor level. Both basic and disease-specific oncology research teams aim toward translational applications of innovative therapies. Candidates will join an environment of multiple collaborative potentials and participate in the academic life of the University and the Medical Center (see recent Time article at www.mc.duke.edu).

Submit letters of interest and CVs to: Keith M. Sullivan, MD, Chief, Division of Medical Oncology and Transplantation, Box 3406, Duke University Medical Center, Durham, NC 27710.

Duke University Medical Center

Duke University Is An Equal Opportunity/Affirmative Action Employer
THE FEDERATION OF EUROPEAN CANCER SOCIETIES
THE AMERICAN ASSOCIATION FOR CANCER RESEARCH
THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY

jointly organize

METHODS IN CLINICAL CANCER RESEARCH
An intensive workshop for European junior clinical oncologists of all disciplines to learn the essentials of clinical trials design

22 - 27 June 1999, Flims, Switzerland
Application Deadline: 15 February 1999

AIMS

• Introduce clinical oncologists in all disciplines to the principles of good clinical trials design.
• Expose clinical scientists to the full spectrum of challenges in clinical cancer research, including surgery, radiotherapy, conventional and investigational antineoplastics, gene therapy, biologic therapy and clinical prevention trials.
• Develop a cadre of well-trained, experienced researchers whose activity will promote better clinical trials design.

FACULTY

*Jean Pierre Armand, Institut Gustave Roussy, Villejuif, France
*Ian F. Tannock, Centre Léon Bérard, Lyon, France
*Daniel D. Von Hoff, Institute for Drug Development, San Antonio, USA
**Matti S. Aapro, Clinique de Genolier, Genolier, Switzerland
Marie-Christine Bissery, Rhône-Poulenc Rorer, Vitry sur Seine, France
George R. P. Blackledge, Zeneca Pharmaceuticals, Macclesfield, England
**Osis W. Brawley, National Cancer Institute, Bethesda, USA
Gregory Burke, Novartis Pharma, Basel, Switzerland
Marc Buyse, ID2, Brussels, Belgium
**Gary M. Clark, University of Texas Health Science Center, San Antonio, USA
**Charles A. Coltman, Jr., Cancer Therapy and Research Center, San Antonio, USA
Ann Cull, Western General Hospital, Edinburgh, Scotland
Jack Cuzick, Imperial Cancer Research Fund, London, England
**Stilik Dalesio, Netherlands Cancer Institute, Amsterdam, The Netherlands
**Janice P. Dutcher, New York Medical College, Bronx, USA
**Alex M.M. Eggermont, University Hospital, Rotterdam, The Netherlands
**William Gullick, Hammersmith Hospital, London, England
Catherine Hill, Institut Gustave Roussy, Villejuif, France
Stanley B. Kaye, University of Glasgow, Glasgow, Scotland
**M. Margaret Kemeny, North Shore University Hospital, Manhasset, USA
**W. Gillies McKenna, University of Pennsylvania, Philadelphia, USA
Max Parmar, MRC Cancer Trials Office, Cambridge, England
Steven Piantadosi, Johns Hopkins Oncology Center, Baltimore, Maryland
**Ross Pinkerton, Royal Marsden NHS Trust, Sutton, England
Eileen Rankin, Ninewells Hospital and Medical School, Dundee, Scotland
**Pierre Scalliet, UCL St.-Luc University Hospital, Brussels, Belgium
Patrick Therasse, EORTC Data Center, Brussels, Belgium
Martine van Glabbeke, EORTC Data Center, Brussels, Belgium
Jacob Verweij, Rotterdam Cancer Institute, Rotterdam, The Netherlands
Nu Viet Vu, University of Geneva, Geneva, Switzerland

*Program Committee Co-Chairpersons
**Program Committee Members

WORKSHOP SESSION FORMATS

The workshop scientific program will consist of three types of activities to serve a variety of didactic needs:
• Lectures will give participants a necessary overview of the field.
• Parallel discussion group sessions will enable participants to discuss specific items in a small session limited to 15 persons.
• During the protocol development sessions each participant will develop a concept sheet for a clinical trial protocol and, through extensive mentoring, design and complete the writing of the clinical trial protocol before the end of the workshop.

TOPICS

Lectures
New targets for cancer treatment
Basic biostatistics for the clinical trialist
Principles of clinical pharmacology
Phase III trials
Ethical issues raised in clinical trials
Radiotherapy in clinical trials
The design of clinical trials related to biological agents
The pitfalls of clinical trials
Design and conduct of Phase I clinical trials
Phase II trials
Regulatory affairs
Preclinical data for clinical trials
Chemoprevention and screening trials

Parallel discussion groups
New measures of outcome: quality of life, clinical benefit, cost benefit
Special problems in clinical trial design: cytostatic agents, angiogenesis inhibitors, growth factors
Special problems in design of clinical trials with biologics
Prognostic factors and screening
Special considerations for surgical oncology trials
The challenge of combined modality trials
Special considerations for radiation oncology trials
Statistics: statistical problems and the concept of meta-analysis

For information please contact the Workshop Secretariat
FECS, Avenue E. Mounier 83, B-1200 Brussels, Belgium
Tel. +32-2-7750202 • Fax +32-2-7750200
e-mail FECS : workshop@fecs.be • AACR : meetings@aacr.org • ASCO : asco@asco.org
ONAH MC TU (Announces cancer trials

The latest news in cancer research & trials

Step-by-step guide to finding clinical trials

Easy access to all clinical trials resources from NCI

Visit us at http://cancertrials.nci.nih.gov
Molecular Determinants of Sensitivity To Antitumor Agents

March 4-8, 1999
Whistler Resort & Conference Centre
Whistler, British Columbia, Canada

CONFERENCE PROGRAM

Keynote Address
Richard D. Klausner / Bethesda, MD

Tumor Physical Environment
Rakesh Jain / Boston, MA
Amato J. Giaccia / Stanford, CA
Robert S. Kerbel / Toronto, Canada
Valerie Weaver / Berkeley, CA

Transport/Cellular Pharmacology
I. David Goldman / Bronx, NY
Carol E. Cass / Edmonton, Canada
Michael M. Gottesman / Bethesda, MD

Drug-Target Interactions
Francis Ali-Osman / Houston, TX
James C. Wang / Cambridge, MA
Susan B. Horwitz / Bronx, NY
Thomas W. Griffin / Nutley, NJ

Responses to Specific Cytotoxic Agents
Josef Jiricny / Zurich, Switzerland
Isabel Mellon / Lexington, KY
Michael B. Kastan / Memphis, TN

Apoptosis I: Drug Responses
Scott H. Kaufmann / Rochester, MN
Janet A. Houghton / Memphis, TN
Kapil N. Bhalla / Atlanta, GA
Craig B. Thompson / Chicago, IL

Apoptosis II: Machinery/Signaling
Eileen White / Piscataway, NJ
Atul Bedi / Baltimore, MD
Avi Ashkenazi / S. San Francisco, CA

Apoptosis III: Targets
Peter J. Houghton / Memphis, TN
Renato Baserga / Philadelphia, PA
Tona M. Gilmer / Research Triangle Park, NC

Registration Deadline: January 4, 1999

Information and Registration Forms:

American Association for Cancer Research
Public Ledger Building, Suite 826
150 South Independence Mall West
Philadelphia, PA 19106-3483
215-440-9300 215-440-9313 (FAX)
E-mail: meetings@aacr.org
Website: http://www.aacr.org
Robert Huebner died on August 26, 1998, at the Veterans Administration Medical Center, Coatesville, PA. He was 84 and had suffered from Alzheimer’s Syndrome for 16 years.

Dr. Huebner’s extensive scientific accomplishments included the discoveries of many viruses responsible for serious respiratory illnesses in children as well as major discoveries in cancer biology, including adenovirus oncogenic activity and adenoviral T-antigens. He also developed immunologic methods for quantitating avian and murine retroviruses, which led to his demonstration of the subviral expression of endogenous retroviruses. These discoveries and the oncogene theories he put forth helped scientists to focus on the search for tumor viruses and oncogenes of humans and led to the development of vaccines and treatments for a variety of viral illnesses.

Dr. Huebner received his M.D. from St. Louis University. Following an internship and service as medical officer in the U.S. Public Health Service (PHS), he joined the Laboratory of Infectious Diseases, National Institutes of Health (NIH), in 1944. He proved his scientific mettle rapidly, identifying disease outbreaks in New York and California as being caused by members of the rickettsia family. Later, with his long-term scientific colleague, Wallace P. Rowe, he isolated and identified adenoviruses and human cytomegalovirus in culture and developed immunologic techniques for identifying a wide array of viral agents.

During his long career at the NIH as a Laboratory Chief at the National Institute of Allergy and Infectious Diseases and later at the National Cancer Institute (NCI), Dr. Huebner trained many scientists and physician-scientists who went on to academic leadership roles throughout the country. His galvanizing leadership and formidable persuasive skills are credited with helping to create a national virus cancer program in the late 1960s, which increased research funding by millions and established a research base for many major discoveries in biology that followed. It is tragic that his illness prevented his wisdom and experience from being mobilized in the fight against the viral epidemics and cancers later identified as a result of his vision.

Dr. Huebner was my scientific mentor for many years at the NIH, where he made it possible for me and others to establish scientific careers in an atmosphere where creativity and drive were constantly encouraged. He had an intuitive sense for the essence of a problem and how to pursue it. He was blunt and outspoken, yet full of warmth and charm, always ready to discuss his latest experiments and ideas as well as to provide advice. His network of collaborators spanned the world, and he stayed in communication with his colleagues through a constant stream of memos and correspondence in an era prior to the advent of faxes or e-mail. He provided an outstanding role model of integrity and leadership, and when I took over responsibility for his NCI laboratory upon his retirement from the PHS in 1977, I had very large shoes to fill, indeed.

Among his many awards, Dr. Huebner received the Presidential National Medal of Science, one of medicine’s highest honors, the Rockefeller Public Service Award, and the Pasteur Medal. He was also a longtime member of the National Academy of Sciences.

Dr. Huebner resided for years on a large farm near Frederick, Maryland, where he and his first wife, Berdie, raised nine children, Elizabeth, Kay, Geraldine, James, Virginia, Edward, Sue, Mary Louise, and Daniel. Kay Huebner has gone on to a distinguished career in cancer research, and she is presently Professor of Microbiology and Immunology at the Kimmel Cancer Institute of Thomas Jefferson University in Philadelphia. Berdie died seven years ago. Dr. Huebner is survived by his second wife, Harriet.

Robert Huebner will be remembered as a great pioneer who vastly expanded the horizons of cancer and infectious disease research.

Stuart A. Aaronson, M.D.
Derald H. Ruttenberg Cancer Center
The Mount Sinai Medical Center
New York, NY